Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > OIG: HHS Must Clamp Down on Off-Label Promotion

Drug Industry Daily

Feb. 3, 2012 | Vol. 11 No. 24

OIG: HHS Must Clamp Down on Off-Label Promotion

Drugmakers could see a stronger crackdown on off-label promotion according to a new Office of Inspector General (OIG) report that directs HHS to focus on the practice.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

Related Articles

DOJ Submits 11th-Hour Appeal of N.Y. Judge’s Plan B Ruling DOJ’s Plan B Stay Request Denied; Judge Sets Noon Deadline The Buzz Orphan Drugmaker Raptor Wins FDA Approval for Lead Product Procysbi

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.